chart is looking very good. We have a couple allt
Post# of 7769
Posted On: 01/10/2015 9:35:57 AM
chart is looking very good. We have a couple alltime technical weekly's highs: 1) volume and 2) accumulation. Everyone is expecting a pullback to give the RSI and accumulation a rest. It appeared yesterday was possibly the start of a retracement, but the price recovered well and we had a good close. Watching the intraday price action today clearly proves that someone or some group is trying very hard to push this stock down. Whether these individuals are shorts, have ill will against certain investors or SCRC leadership, a group of large investors trying to shake the trees to pick up cheaper stock, daytraders or a combination of or more of these groups is anyone's guess. I really have no opinion on the matter. But once again, the bulls won the tug-a-war this week. And as much as I can see a retracement, I could also see new buying pressure based on the technicals or fundamentals or both.
Any day the company can publish a release that takes all of us by surprise, which has the power to take this stock into orbit. Bob has not given up on RapiMeds, nor have I. I stay in continuous contact with large, privately-owned compounding pharmacies that sell their topical creams in all 50 states. These companies are headquartered in different parts of the country, target the same doctors and patients that SCRC's targets, and the generate monthly revenues between $1 million and $25 million. The ExpressScripts phase three change was to occur on January 1st, not January 15th as many here have stated. I posted you the proof of this last week. None of the compounding pharmacies with whom I maintain continuous contact have seen any significant reduction in adjudication rates or reimbursements since the first of the year. In fact, management at each company believes the biggest impact occurred during phases one and two (July 15 and September 15 respectfully). I use this data to support my investment thesis that the same holds true for Scrips's compounding business, and I fully expect January-March to result in at least $15 million in approved orders from Main Ave. And if the company is able to get moving with the other pharmacies, PIMD or RapiMeds, all the technical indications hinting at a retracement mean absolutely nothing, as this stock will go nuclear. as always Go SCRC! Tut
Any day the company can publish a release that takes all of us by surprise, which has the power to take this stock into orbit. Bob has not given up on RapiMeds, nor have I. I stay in continuous contact with large, privately-owned compounding pharmacies that sell their topical creams in all 50 states. These companies are headquartered in different parts of the country, target the same doctors and patients that SCRC's targets, and the generate monthly revenues between $1 million and $25 million. The ExpressScripts phase three change was to occur on January 1st, not January 15th as many here have stated. I posted you the proof of this last week. None of the compounding pharmacies with whom I maintain continuous contact have seen any significant reduction in adjudication rates or reimbursements since the first of the year. In fact, management at each company believes the biggest impact occurred during phases one and two (July 15 and September 15 respectfully). I use this data to support my investment thesis that the same holds true for Scrips's compounding business, and I fully expect January-March to result in at least $15 million in approved orders from Main Ave. And if the company is able to get moving with the other pharmacies, PIMD or RapiMeds, all the technical indications hinting at a retracement mean absolutely nothing, as this stock will go nuclear. as always Go SCRC! Tut
(0)
(0)